China isn’t Asia. That’s certainly one take-away from the 2013 BIO Convention in China, or BIO China. The learning curve is steep for Western biopharmas seeking a toehold in Asia’s largest market, with 1 .4 billion people, and if companies accustomed to doing business in Japan and South Korea expect the same conditions in China, they’re doomed to disappointment.